Sun Sep 15 11:15:08 UTC 2024: ## Hedge Funds Show Interest in Abrdn Life Sciences Investors (HQL)

**New York, NY** – Several hedge funds have recently adjusted their holdings in Abrdn Life Sciences Investors (NYSE:HQL), indicating growing interest in the closed-ended equity mutual fund.

Wedbush Securities Inc. increased its stake in HQL by 8.2% during the second quarter, bringing its total holdings to $236,000. Other notable changes include:

* **Janney Montgomery Scott LLC** increased its holdings by 13.5% in the fourth quarter.
* **Kingsview Wealth Management LLC** increased its holdings by 2.5% in the fourth quarter.
* **Cornerstone Advisors LLC** significantly increased its holdings by 73.7% in the fourth quarter.
* **RPO LLC** increased its holdings by 3.5% in the fourth quarter.
* **Quantedge Capital Pte Ltd** increased its holdings by 30.4% in the fourth quarter.

Overall, hedge funds and other institutional investors currently own 32.21% of HQL’s stock.

In other news, Saba Capital Management, L.P. purchased 13,812 shares of HQL stock on June 24th for a total transaction of $194,472.96. This brings the insider’s total ownership to 3,429,891 shares, valued at $48,292,865.28.

Abrdn Life Sciences Investors focuses on investing in public equity markets across the globe, specifically targeting companies in the life sciences sector. This includes industries like biotechnology, pharmaceuticals, diagnostics, and managed healthcare.

HQL opened at $15.28 on Friday. The stock’s 50-day moving average price is $15.16 and its 200-day moving average price is $14.15. The stock has a 52-week low of $11.34 and a 52-week high of $15.90.

To stay up-to-date on the latest news and analyst ratings for Abrdn Life Sciences Investors, you can subscribe to MarketBeat.com’s free daily email newsletter.

Read More